Selected research
Market Structure
Global Antisense Oligonucleotides Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Antisense Oligonucleotides Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Antisense Oligonucleotides Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Antisense Oligonucleotides Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antisense Oligonucleotides Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Antisense Oligonucleotides Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Antisense Oligonucleotides Drugs include Akcea Therapeutics, Ionis Pharmaceuticals and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Antisense Oligonucleotides Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Antisense Oligonucleotides Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Antisense Oligonucleotides Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antisense Oligonucleotides Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Antisense Oligonucleotides Drugs Segment by Company
Akcea Therapeutics
Ionis Pharmaceuticals
AstraZeneca
Antisense Oligonucleotides Drugs Segment by Type
Inotersen
Eplontersen
Other
Antisense Oligonucleotides Drugs Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Antisense Oligonucleotides Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense Oligonucleotides Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antisense Oligonucleotides Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense Oligonucleotides Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Antisense Oligonucleotides Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotides Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antisense Oligonucleotides Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Antisense Oligonucleotides Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Inotersen
- Eplontersen
- Other
Applications
- Hospital and Clinic
- Retail Pharmacies
- Other
Companies covered
- Akcea Therapeutics
- Ionis Pharmaceuticals
- AstraZeneca
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Antisense Oligonucleotides Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Antisense Oligonucleotides Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Antisense Oligonucleotides Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Antisense Oligonucleotides Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Antisense Oligonucleotides Drugs Market Dynamics
- 2.1 Antisense Oligonucleotides Drugs Industry Trends
- 2.2 Antisense Oligonucleotides Drugs Industry Drivers
- 2.3 Antisense Oligonucleotides Drugs Industry Opportunities and Challenges
- 2.4 Antisense Oligonucleotides Drugs Industry Restraints
3 Antisense Oligonucleotides Drugs Market by Manufacturers
- 3.1 Global Antisense Oligonucleotides Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Antisense Oligonucleotides Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Antisense Oligonucleotides Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Antisense Oligonucleotides Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Antisense Oligonucleotides Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Antisense Oligonucleotides Drugs Manufacturers, Product Type & Application
- 3.7 Global Antisense Oligonucleotides Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Antisense Oligonucleotides Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Antisense Oligonucleotides Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Antisense Oligonucleotides Drugs Tier 1, Tier 2, and Tier 3
4 Antisense Oligonucleotides Drugs Market by Type
- 4.1 Antisense Oligonucleotides Drugs Type Introduction
- 4.1.1 Inotersen
- 4.1.2 Eplontersen
- 4.1.3 Other
- 4.2 Global Antisense Oligonucleotides Drugs Sales by Type
- 4.2.1 Global Antisense Oligonucleotides Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Antisense Oligonucleotides Drugs Sales by Type (2021-2032)
- 4.2.3 Global Antisense Oligonucleotides Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Antisense Oligonucleotides Drugs Revenue by Type
- 4.3.1 Global Antisense Oligonucleotides Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Antisense Oligonucleotides Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Antisense Oligonucleotides Drugs Revenue Market Share by Type (2021-2032)
5 Antisense Oligonucleotides Drugs Market by Application
- 5.1 Antisense Oligonucleotides Drugs Application Introduction
- 5.1.1 Hospital and Clinic
- 5.1.2 Retail Pharmacies
- 5.1.3 Other
- 5.2 Global Antisense Oligonucleotides Drugs Sales by Application
- 5.2.1 Global Antisense Oligonucleotides Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Antisense Oligonucleotides Drugs Sales by Application (2021-2032)
- 5.2.3 Global Antisense Oligonucleotides Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Antisense Oligonucleotides Drugs Revenue by Application
- 5.3.1 Global Antisense Oligonucleotides Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Antisense Oligonucleotides Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Antisense Oligonucleotides Drugs Revenue Market Share by Application (2021-2032)
6 Global Antisense Oligonucleotides Drugs Sales by Region
- 6.1 Global Antisense Oligonucleotides Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Antisense Oligonucleotides Drugs Sales by Region (2021-2032)
- 6.2.1 Global Antisense Oligonucleotides Drugs Sales by Region (2021-2026)
- 6.2.2 Global Antisense Oligonucleotides Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Antisense Oligonucleotides Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Antisense Oligonucleotides Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Antisense Oligonucleotides Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Antisense Oligonucleotides Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Antisense Oligonucleotides Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Antisense Oligonucleotides Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Antisense Oligonucleotides Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Antisense Oligonucleotides Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Antisense Oligonucleotides Drugs Revenue by Region
- 7.1 Global Antisense Oligonucleotides Drugs Revenue by Region
- 7.1.1 Global Antisense Oligonucleotides Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Antisense Oligonucleotides Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Antisense Oligonucleotides Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Antisense Oligonucleotides Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Antisense Oligonucleotides Drugs Revenue (2021-2032)
- 7.2.2 North America Antisense Oligonucleotides Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Antisense Oligonucleotides Drugs Revenue (2021-2032)
- 7.3.2 Europe Antisense Oligonucleotides Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Antisense Oligonucleotides Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Antisense Oligonucleotides Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Antisense Oligonucleotides Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Antisense Oligonucleotides Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Akcea Therapeutics
- 8.1.1 Akcea Therapeutics Company Information
- 8.1.2 Akcea Therapeutics Business Overview
- 8.1.3 Akcea Therapeutics Antisense Oligonucleotides Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Akcea Therapeutics Antisense Oligonucleotides Drugs Product Portfolio
- 8.1.5 Akcea Therapeutics Recent Developments
- 8.2 Ionis Pharmaceuticals
- 8.2.1 Ionis Pharmaceuticals Company Information
- 8.2.2 Ionis Pharmaceuticals Business Overview
- 8.2.3 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs Product Portfolio
- 8.2.5 Ionis Pharmaceuticals Recent Developments
- 8.3 AstraZeneca
- 8.3.1 AstraZeneca Company Information
- 8.3.2 AstraZeneca Business Overview
- 8.3.3 AstraZeneca Antisense Oligonucleotides Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 AstraZeneca Antisense Oligonucleotides Drugs Product Portfolio
- 8.3.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Antisense Oligonucleotides Drugs Value Chain Analysis
- 9.1.1 Antisense Oligonucleotides Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Antisense Oligonucleotides Drugs Production Mode & Process
- 9.2 Antisense Oligonucleotides Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Antisense Oligonucleotides Drugs Distributors
- 9.2.3 Antisense Oligonucleotides Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst